[1] Schuetz P, Albrich WC,Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions[J].BMC Med,2011,9:107.doi:10.1186/1471-7015-9-107.[2] Ruiz-Rodríguez J,Rello J. Predicting treatment failure in severe sepsis and septic shock[J]. Crit Care,2013,17(5):180.doi:10.1186/cc12877.[3] Schuetz P,Maurer P,Punjabi V,et al. Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients[J]. Crit Care,2013,17(3):R115.[4] 降钙素原急诊临床应用专家共识组.降钙素原急诊临床应用的专家共识[J].中华急诊医学杂志,2012,21(9):944-951.[5] 中华医学会呼吸病学分会. 社区获得性肺炎诊断和治疗指南[J]. 中华结核和呼吸杂志, 2006, 29(10):651-655.[6] 何礼贤.降钙素原指导严重细菌感染和脓毒血症诊疗的临床意义[J].中华结核和呼吸杂志,2012,35(8):636-637.[7] Jekarl DW,Lee SY,Lee J,et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis[J]. Diagn Microbiol Infect Dis,2013,75(4):342-347.[8] Krüger S,Ewig S,Marre R,et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31(2):349-355.[9] Espaa PP,Capelastegui A,Bilbao A,et al. Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia [J]. Eur J Clin Microbiol Infect Dis,2012,31(12):3397-3405.[10] Nyamande K,Lalloo UG.Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP [J].Int J Tuberc Lung Dis,2006,10(5):510-515.[11] Huang DT,Weissfeld LA,Kellum JA,et al.Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J].Ann Emerg Med, 2008,52(1):48-58.[12] Johansson N,Kalin M,Backman-Johansson C,et al. Procalcitonin levels in community-acquired pneumonia correlation with aetiology and severity[J]. Scand J Infect Dis,2014,46(11):787-791.[13] Park JH,Wee JH,Choi SP,et al.The value of procalcitonin level in community-acquired pneumonia in the ED[J].Am J Emerg Med,2012,30 (7):1248-1254.[14] Kim JH,Seo JW,Mok JH,et al.Usefulness of plasma procalcitonin to predict severity in elderly patients in community-acquired pneumonia [J]. Tuberc Respir Dis (Seoul),2013,74 (5):207-214.[15] Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections[J].Clin Microbiol Infect,2011,17(Suppl 6):E1-E59.[16] Schuetz P,Briel M,Mueller B,et al. Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections [J].JAMA,2013,309(7):717-718.[17] Stolz D,Christ-Crain M,Bingisser R,et al. Antibiotic treatment of exacerbations of COPD:a randomized,controlled trial comparing procalcitonin guidance with standard therapy[J].Chest,2007,131(1):9-19.[18] Fazili T,Endy T,Javaid W,et al. Role of procalcitonin in guiding antibiotic therapy[J]. Am J Health Syst Pharm,2012,69 (23):2057-2061.[19] Albrich WC,Dusemund F,Bucher B,et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in "real life":an international,multicenter post study survey (ProREAL) [J]. Arch Intern Med,2012,172 (9):715-722.[20] Schuetz P,Chiappa V,Briel M,et al. Procalcitonin algorithms for anti-biotic therapy decisions:a systematic review of randomized controlled trials and recommendations for clinical algorithms[J].Arch Intern Med,2011,171(15):1322-1271.[21] 郭娟,陈国勇,杨霄,等. 血清降钙素原水平在肝移植术后并发肺部感染患者中的诊断价值[J].中国老年学杂志,2014,34(22):6245-6247.[22] 蔡川奇,林志鸿,蔺佩鸿,等.血清白蛋白和前白蛋白对老年肺炎病情的预测价值[J].中国老年学杂志,2014,34(1):103-105. |